Glenmark’s FabiFlu, covid-19 medicine to treat mild to moderate coronavirus

Glenmark’s FabiFlu, covid-19 medicine to treat mild to moderate coronavirus: It is not a magic bullet as it is not the only thing we have to give. This is not a specific drug made for COVID-19 and has been found to be useful, but how much it will be useful we will have to see.Mumbai, India; June 20, 2020: In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced the launch of antiviral drug Favipiravir (brand name FabiFlu®) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu® the first oral Favipiravir-approved medication in India for the treatment of COVID-19

     Glenmark’s FabiFlu, covid-19 medicine to treat mild to       moderate coronavirus

The pharma company said that it has received Indian regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 infections.In a major Coronavirus treatment breakthrough, Glenmark Pharmaceuticals' FabiFlu is the first oral favipiravir-approved medication in India for the treatment of COVID-19. Favipiravir can be used for coronavirus patients with co-morbid conditions such as diabetes and heart disease with mild to moderate COVID-19 symptoms hoping it will prevent the virus from multiplying in the patient's body. Doctors and health experts have asked people to be very careful and not do self medication. This is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14. It may also vary from case to case, so please do not try to treat yourself, it will do more harm than good.  Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 at a price of about Rs 103 per tablet. The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.Considering a minimum of two strips per patient, Glenmark said it will be able to provide FabiFlu for about 82,500 patients in the 1st month itself. They will then scale up and meet the healthcare needs of the country."It is not a magic bullet as it is not the only thing we have to give. This is not a specific drug made for COVID-19 and has been found to be useful, but how much it will be useful we will have to see.Mumbai, India; June 20, 2020: In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced the launch of antiviral drug Favipiravir (brand name FabiFlu®) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu® the first oral Favipiravir-approved medication in India for the treatment of COVID-19.Glenmark pharma share price surged 27 percent, hitting upper circuit of Rs 572.70 per share on the BSE, after the pharma company said it received Indian regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 infections in the country.The stock, which has surged over 153 percent in the last three months, ended at Rs 519.80, up Rs 110.70, or 27.06 percent. It has touched a 52-week high of Rs 572.70.It traded with volumes of 4,632,815 shares, compared to its five day average of 175,549 shares, an increase of 2,539.04 percent.Cipla launched a generic of Remdesivir under brand name Cipremi to treat patients with severe symptoms. This comes as Gilead Sciences Inc. extended a voluntary non-exclusive licence to Cipla to manufacture and market the copy-cat version of its anti-viral drug. India, earlier this month, had approved the emergency use of Gilead’s Remdesivir.This is a short-term opportunity, nothing great to count on. Once there will be more competition, this will not be of much benefit,” Surajit Pal, pharma analyst at Prabhudas Lilladher, told BloombergQuint. “There are six other players developing Remdesivir, the likes of Hetero, Cadila, Jubilant lifeSciences, Strides Pharma. In case of Glenmark, there will be another two-three players entering. Remdesivir won’t contribute anything to the bottom line.” Agreed Vishal Manchanda, analyst at Nirmal Bang Securities, as he said a total of six companies, including Jubilant lifeSciences, Cadila and Hetero, are developing Remdesvir. There will be more players for Glenmark’s drug as well.It is an oral product which means, hospitalisation may not be necessary so it will take away the burden on the hospitals and healthcare staff to some extent. The medicine is said to result in the rapid reduction in viral load within four days and provides faster symptomatic and radiological improvement. Favipiravir has shown clinical improvement of up to 88 per cent in mild to moderate COVID-19 cases, it said. Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It remains to be seen whether this tablet becomes a game changer in the days to come

If you liked this post, I’d be very grateful if you’d help it spread by emailing it to a friend, or sharing it on Twitter, Instagram or Facebook. you may follow us on Instagram , Facebook  or Twitter Thank you from heart."Glenmark’s FabiFlu, covid-19 medicine to treat mild to moderate coronavirus"https://untoldstoris.blogspot.com/2020/06/glenmarks-fabiflu-covid-19-medicine-to.html